Plain Language Summary

What is it about? The study investigates how Medicare may set initial price offers for drugs selected in the second round of its Drug Price Negotiation Program. The existing gap this study fills involves integrating statutory price benchmarks with clinical effectiveness data to arrive at the initial price offer. By providing a structured approach to evaluate and negotiate drug prices, the paper offers a potential solution to make the Drug Price Negotiation Program more transparent and aligned with therapeutic value.

How was the research conducted? The 15 drugs included in the study were selected based on their inclusion in Medicare’s negotiation program. The research was based on a methodological concept that combines price benchmarks with clinical effectiveness for setting the initial price offer. This approach was applied by constructing a list of therapeutic alternatives for each drug and evaluating them using various price benchmarks and clinical effectiveness evidence. Researchers analyzed data from network meta-analyses, clinical guidelines, and assessments from the Institute for Clinical and Economic Review. The study used an evidence rating scheme to compare prices and therapeutic alternatives. This method was chosen to provide a comprehensive assessment of each drug's value relative to its alternatives.

What were the results? The study's main finding was that integrating statutory discounts and comparative clinical effectiveness can guide initial price offers, leading to significant potential savings. Across the drugs studied, estimated discounts ranged from 32% to 78% off list price. An important additional finding was that drugs with primarily generic or biosimilar alternatives received larger discounts compared to those with branded alternatives.

Why are the results important? These findings provide key insights and transparency into how drug prices are negotiated by Medicare.

What are the strengths and weaknesses of this study? The study's main strength lies in its comprehensive approach, combining price benchmarks with clinical data. A limitation is the reliance on publicly available data, which may not capture all factors considered in negotiations.

^{Note: This content was created with assistance from artificial intelligence (AI) and has been reviewed and edited by ISPOR staff. For more information or for inquiries on ISPOR’s AI policy, click here or contact us at info@ispor.org.}